A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination
with Toripalimab，The study is designed to determine the safety ，tolerability and antitumor
activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.